<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neonatal thrombocytopenia: Etiology</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neonatal thrombocytopenia: Etiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neonatal thrombocytopenia: Etiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caraciolo J Fernandes, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Garcia-Prats, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thrombocytopenia, defined as a platelet count &lt;150,000/microL [<a href="#rid1">1</a>], occurs more often during the neonatal period than in older populations. In particular, the risk and severity of thrombocytopenia increases for newborns admitted to neonatal intensive care units (NICUs). Thrombocytopenia is associated with increased risk of bleeding, and severe thrombocytopenia (platelet count &lt;50,000/microL) is associated with significant morbidity. As a result, it is important to identify at-risk infants, and if needed, to initiate therapy to prevent complications. </p><p>The etiology of neonatal thrombocytopenia in the newborn is reviewed here. The evaluation and general management of neonatal thrombocytopenia are discussed separately. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Neonatal thrombocytopenia is defined as a platelet count &lt;150,000/microL. This is the same definition used in adults, which corresponds to the 5<sup>th</sup> percentile for a normal adult population (ie, approximately 5 percent of adults have platelet counts below this level). However, it is important to note that a considerably higher percentage of newborns, particularly preterm neonates, will present with thrombocytopenia [<a href="#rid2">2-4</a>].<em> </em>(See <a class="local">'Epidemiology'</a> below.)</p><p>Thrombocytopenia is classified by severity depending on the platelet count:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Platelet count 100,000 to &lt;150,000/microL.</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Platelet count 50,000 to 99,000/microL.</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Platelet count &lt;50,000/microL. Severe thrombocytopenia is associated with an increased risk of bleeding resulting in morbidity or death [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H1000925847"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Healthy preterm and term newborns are more likely to be thrombocytopenic with platelet counts below &lt;150,000/microL than adults and older children [<a href="#rid3">3,4,6</a>]. The risk of thrombocytopenia increases with decreasing gestational age (GA). One study of 34,146 neonates (GA from 22 to 42 weeks) reported the 5<sup>th</sup> percentile for neonates was lower than the standard adult value of 150,000/microL and decreased with decreasing GA [<a href="#rid4">4</a>]. For example, the 5<sup>th</sup> percentile was 104,200/microL for infants below 32 weeks gestational age (GA) and was 123,100/microL for late preterm (34 to 36 weeks GA) and term (GA greater than 37 weeks) infants. Platelet counts increased with advancing postnatal age.</p><p>Reported predisposing factors for neonatal thrombocytopenia include chronic fetal hypoxia related to pregnancy-related maternal hypertension, maternal diabetes, preterm birth, sepsis, asphyxia, intrauterine growth restriction (birth weight [BW] &lt;10<sup>th</sup> percentile for GA), and necrotizing enterocolitis (NEC) [<a href="#rid1">1,7,8</a>].</p><p class="headingAnchor" id="H1934542904"><span class="h2">Severe thrombocytopenia</span><span class="headingEndMark"> — </span>Severe neonatal thrombocytopenia is uncommon in the general healthy newborn population, with a reported incidence between 0.14 and 0.24 percent [<a href="#rid2">2,9</a>]. However, infants admitted to the neonatal intensive care unit (NICU) have a higher risk of severe thrombocytopenia, with a reported risk between 2.4 and 5 percent [<a href="#rid10">10,11</a>]. Data from NICUs in the United Kingdom demonstrated that 5 percent of infants admitted to NICUs had a platelet count &lt;60,000/microL and 60 percent of these patients received platelet transfusions [<a href="#rid12">12</a>]. </p><p>The risk of severe thrombocytopenia (platelet count &lt;50,000/microL) increases with decreasing GA [<a href="#rid4">4,13,14</a>]. The risk is greatest in the most preterm infants (GA &lt;28 weeks) as illustrated in a retrospective study of 284 extremely low birth weight (ELBW) infants (BW &lt;1000 g) born between 2003 and 2004 that reported 28 percent of patients had severe thrombocytopenia, 56 percent had platelet counts of &lt;100,000/microL, and 73 percent of patients had platelet counts of &lt;150,000/microL within the first three days of life [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLASSIFICATION OF ETIOLOGY</span><span class="headingEndMark"> — </span>Causes of thrombocytopenia can be classified by several different methods including:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet size (large, normal, and small)</p><p class="bulletIndent1"><span class="glyph">●</span>Mode of acquisition (congenital or acquired)</p><p class="bulletIndent1"><span class="glyph">●</span>Timing of presentation – Early (&lt;72 hours of age) or late (≥72 hours of age) onset</p><p class="bulletIndent1"><span class="glyph">●</span>Gestational age (GA)</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanisms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased destruction (including sequestration/pooling and activation/consumption of platelets)</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased production of platelets</p><p></p><p>These classifications are useful in the diagnostic evaluation of neonatal thrombocytopenia as summarized in the figure  (<a class="graphic graphic_algorithm graphicRef98573" href="/d/graphic/98573.html" rel="external">algorithm 1</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/97752.html" rel="external">"Neonatal thrombocytopenia: Clinical manifestations, evaluation, and management", section on 'Diagnostic evaluation to identify underlying cause'</a>.)</p><p>This review will describe the most common causes of neonatal thrombocytopenia based on the underlying mechanism of thrombocytopenia  (<a class="graphic graphic_table graphicRef52668" href="/d/graphic/52668.html" rel="external">table 1</a>) [<a href="#rid5">5,15</a>]. Case series report that a cause of thrombocytopenia is identified in approximately 50 to 75 percent of infants admitted to neonatal intensive care units (NICUs) [<a href="#rid7">7,8</a>]. </p><p class="headingAnchor" id="H6"><span class="h1">INCREASED DESTRUCTION</span><span class="headingEndMark"> — </span>Increased platelet destruction is the most common mechanism for neonatal thrombocytopenia and is seen in a number of neonatal conditions. In particular, thrombocytopenia due to an underlying destructive immunologic mechanism is a common cause of early-onset neonatal thrombocytopenia, especially in otherwise healthy term newborns. This is caused by the placental crossing of maternal antibodies, which destroy neonatal platelets. In a French prospective study, the incidence of immune thrombocytopenia, (defined as a platelet count &lt;150,000/microL) in the general newborn population was estimated at 0.3 percent [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2159405444"><span class="h2">Immune-mediated thrombocytopenia</span><span class="headingEndMark"> — </span>Immune-mediated processes are among the most common causes of neonatal thrombocytopenia. Autoantibodies, drug-dependent antibodies, or alloantibodies mediate platelet destruction through interaction with platelet membrane antigens or by forming immune complexes, which can bind to reticuloendothelial cell Fc receptors leading to platelet clearance from the circulation. </p><p>In neonates, causes of immune-mediated thrombocytopenia include (see  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal alloimmune thrombocytopenia (NAIT)</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal autoimmune thrombocytopenia </p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced thrombocytopenia due to drug-dependent antibodies</p><p></p><p class="headingAnchor" id="H4077923762"><span class="h3">Neonatal alloimmune thrombocytopenia</span><span class="headingEndMark"> — </span>Neonatal alloimmune thrombocytopenia (NAIT), also referred to as fetal and neonatal alloimmune thrombocytopenia (FNAIT), occurs when fetal platelets contain an antigen inherited from the father that the mother lacks. During pregnancy, the mother forms immunoglobulin G (IgG)-class antiplatelet antibodies against the "foreign" antigen, which cross the placenta and destroy fetal (FNAIT) and neonatal (NAIT) platelets that express the paternal antigen. The clinical manifestations, diagnosis, and management of NAIT are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal alloimmune thrombocytopenia'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Neonatal autoimmune thrombocytopenia</span><span class="headingEndMark"> — </span>Neonatal autoimmune thrombocytopenia is mediated by maternal antibodies that react with both maternal and fetal platelets. This occurs in maternal autoimmune disorders, including immune thrombocytopenia and systemic lupus erythematosus (SLE). The diagnosis usually is apparent from the mother's medical history and the presence of maternal thrombocytopenia. However, the platelet count of affected mothers may be normal after a splenectomy or if there is sufficient compensatory thrombopoiesis. Mothers of infants with unexplained neonatal thrombocytopenia should be investigated for the presence of an autoimmune disorder, as neonatal thrombocytopenia can be the initial presenting sign [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Immune thrombocytopenia (ITP)'</a>.)</p><p>Healthy women without a history of an autoimmune disorder sometimes develop gestational thrombocytopenia that usually is mild [<a href="#rid2">2,18</a>]. This condition may be a mild and transient form of ITP and is considered benign. Neonatal thrombocytopenia is rare. (See  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Gestational thrombocytopenia (GT)'</a>.)</p><p>The clinical manifestations, diagnosis, and management of neonatal autoimmune thrombocytopenia are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal autoimmune thrombocytopenia'</a>.)</p><p class="headingAnchor" id="H12445777"><span class="h2">Sequestration and trapping</span><span class="headingEndMark"> — </span>Causes of thrombocytopenia due to sequestration and trapping in the neonate are uncommon and include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersplenism</strong> – Thrombocytopenia may be associated with an enlarged spleen. Underlying disorders resulting in splenomegaly include hemolytic anemia, congenital hepatitis due to viral infection, and portal vein thrombosis [<a href="#rid19">19</a>]. The clinical features depend upon the associated condition. Management includes identification and treatment of the underlying cause. Platelet transfusions are given as needed. Splenectomy, often considered in the older child or adult, is rarely needed in the neonatal period. (See  <a class="medical medical_review" href="/d/html/5928.html" rel="external">"Approach to the child with an enlarged spleen"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kasabach-Merritt phenomenon</strong> – Kasabach-Merritt is associated with kaposiform hemangioendothelioma, an aggressive form of giant hemangioma, and not true common hemangiomas of infancy. Thrombocytopenia results from shortened platelet survival caused by sequestration of platelets in the vascular malformation with platelet activation and consumption. (See  <a class="medical medical_review" href="/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)", section on 'Kasabach-Merritt phenomenon'</a>.)</p><p></p><p class="headingAnchor" id="H12445879"><span class="h2">Platelet activation and consumption</span></p><p class="headingAnchor" id="H22"><span class="h3">Disseminated intravascular coagulation</span><span class="headingEndMark"> — </span>Disseminated intravascular coagulation (DIC) is a systemic process producing both thrombosis and hemorrhage. It is a secondary disorder caused by activation of the coagulation system by tissue damage from a variety of primary underlying diseases (eg, sepsis, asphyxia, meconium aspiration, necrotizing enterocolitis, or severe neonatal respiratory distress syndrome) [<a href="#rid3">3,20</a>]. The diagnosis is based on both clinical findings (eg, hemorrhage and thrombocytopenia in a patient with a predisposing medical condition) and abnormal coagulation studies. Confirming laboratory studies include prolonged prothrombin time, prolonged activated partial thromboplastin time, decreased plasma fibrinogen concentration, and increased fibrin degradation product or D-dimer levels. (See  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children", section on 'Diagnosis'</a>.)</p><p>The causes, diagnosis and management of neonatal DIC are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children"</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Thrombosis</span><span class="headingEndMark"> — </span>Thrombocytopenia often accompanies thrombosis in newborns. The risk of thrombosis is increased by the presence of an indwelling catheter, or by medical conditions predisposing to thrombosis, including prematurity and sepsis. Renal vein thrombosis is the most common form of neonatal thrombosis that is <strong>not</strong> associated with an indwelling catheter. Patients should be evaluated for a thromboembolic disorder if thrombocytopenia cannot be explained by other conditions. (See  <a class="medical medical_review" href="/d/html/5912.html" rel="external">"Neonatal thrombosis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H169998109"><span class="h3">Type 2B von Willebrand disease</span><span class="headingEndMark"> — </span>In type 2B von Willebrand disease (vWD), the structurally abnormal von Willebrand factor has increased affinity for its receptor (glycoprotein IB) on the platelet [<a href="#rid21">21-23</a>]. This may lead to formation of small platelet aggregates, which are cleared from the circulation resulting in a lower platelet count. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease", section on 'Abnormalities in the CBC and coagulation tests'</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">DECREASED PRODUCTION</span><span class="headingEndMark"> — </span>Causes of neonatal thrombocytopenia due to decreased platelet production include genetic disorders and diseases associated with bone marrow infiltration or suppression. In addition, early thrombocytopenia associated with intrauterine growth restriction (IUGR) due to decreased platelet production is frequently seen in neonates born to mothers with preeclampsia or other causes of placental insufficiency, particularly preterm infants [<a href="#rid24">24,25</a>].</p><p class="headingAnchor" id="H260888198"><span class="h2">Preeclampsia</span><span class="headingEndMark"> — </span>Thrombocytopenia due to decreased production is common in infants of mothers with preeclampsia and other hypertensive disorders of pregnancy [<a href="#rid26">26</a>]. The incidence of neonatal thrombocytopenia associated with this preeclampsia has been estimated at 1 per 100 live births, and it is more likely to occur in preterm infants [<a href="#rid3">3,26</a>]. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p>In affected infants, thrombocytopenia typically is noted at birth or in the first few days after delivery. The nadir is reached at two to four days of age, with resolution by day 7 to 10 [<a href="#rid3">3</a>]. </p><p>Neutropenia is a common accompanying finding and is caused by decreased production mediated by an inhibitor of neutrophil production [<a href="#rid27">27,28</a>]. It is likely that the associated thrombocytopenia is caused by a similar mechanism [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Genetic disorders</span><span class="headingEndMark"> — </span>Genetic disorders can result in isolated thrombocytopenia or thrombocytopenia associated with other clinical findings.</p><p class="headingAnchor" id="H2983804536"><span class="h3">Congenital platelet disorders</span><span class="headingEndMark"> — </span>Genetic disorders associated with thrombocytopenia due to decreased production are numerous but rare. These disorders as well as those associated with platelet dysfunction are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5921.html" rel="external">"Causes of thrombocytopenia in children", section on 'Inherited platelet disorders'</a> and  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a> and  <a class="medical medical_review" href="/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)", section on 'Specific disorders'</a>.)</p><p class="headingAnchor" id="H31"><span class="h3">Chromosome abnormalities</span><span class="headingEndMark"> — </span>Thrombocytopenia may occur in infants with chromosome abnormalities, including trisomies 21, 18, and 13 and Turner syndrome, although the incidence in most of these conditions is not known. In a case series of 226 neonates with Down syndrome, 66 percent had thrombocytopenia in the first week of life, and 6 percent had platelet counts &lt;50,000/microL [<a href="#rid29">29</a>].</p><p>Chromosomal abnormalities also contribute to a significant proportion of mild thrombocytopenia detected in utero. In a report of 247 cases of platelet counts &lt;150,000/microL detected by consecutive fetal blood sampling, chromosomal abnormality was the etiology in 43 fetuses (17 percent) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H33"><span class="h2">Infiltrative disorders</span><span class="headingEndMark"> — </span>Rarely, bone marrow infiltrative disorders (neonatal leukemia or neuroblastoma) can cause decreased platelet production. However, these are rare in the neonatal period. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma", section on 'Newborns'</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">MISCELLANEOUS CAUSES</span><span class="headingEndMark"> — </span>Thrombocytopenia is associated with a variety of conditions that cannot be classified easily or are associated with more than one pathologic mechanism. In some conditions categorized as miscellaneous (eg, bacterial sepsis and asphyxia), both increased destruction and suppressed bone marrow production may contribute to thrombocytopenia [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H12445967"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Thrombocytopenia caused by bacteria, viral, and fungal infections may be the result of more than one pathogenetic mechanism. In most cases of bacterial sepsis, thrombocytopenia is caused by increased platelet destruction. However, in infants with severe infections, thrombocytopenia is caused by platelet destruction and consumption due to disseminated intravascular coagulation (DIC) combined with inadequate upregulation of platelet production in the bone marrow [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Destructive mechanisms</strong> for thrombocytopenia induced by bacterial sepsis include DIC, endothelial damage, antibody-mediated injury, platelet apoptosis induced by gram-negative bacteria, loss of sialic acid from the platelet membrane caused by neuraminidase-producing bacteria, and platelet aggregation caused by adherence of bacterial products to platelet membranes [<a href="#rid3">3,19</a>]. (See  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children", section on 'Sepsis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased platelet production</strong> due to injury to the megakaryocytes in bone marrow or suppression of megakaryopoiesis by bacterial products.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral infection – Thrombocytopenia may occur with congenital viral infections, including herpes simplex virus (HSV), human immunodeficiency virus (HIV), rubella, and cytomegalovirus (CMV) [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Destructive mechanisms</strong> include platelet aggregation, loss of sialic acid from the platelet membrane caused by viral neuraminidase, splenomegaly, and reticuloendothelial hyperactivity [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased production</strong> may be caused by viral effects on the megakaryocytes [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal infection – Platelet consumption can be seen in fungal infections, sometimes associated with catheter-related thrombosis or DIC. (See  <a class="medical medical_review" href="/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates"</a>.)</p><p></p><p class="headingAnchor" id="H37"><span class="h2">Asphyxia</span><span class="headingEndMark"> — </span>Thrombocytopenia is more common in infants with birth asphyxia than in those without birth asphyxia [<a href="#rid8">8,34-36</a>]. The underlying mechanism is uncertain, although there are data that suggest hypoxia contributes to a decrease in platelet production. However, asphyxia is also associated with DIC, which may cause platelet activation and consumption [<a href="#rid3">3,34,37</a>].</p><p>Based on retrospective case series, one-third to one-half of neonates with perinatal asphyxia developed thrombocytopenia (platelet count &lt;150,000/microL) that presented within the first 48 hours of life, with a nadir occurring on the third day of life [<a href="#rid34">34,37</a>]. Thrombocytopenia is generally mild and transient, and most patients will not require platelet transfusions. </p><p>Therapeutic hypothermia started within the first six hours after delivery is the only proven neuroprotective intervention for hypoxic-ischemic encephalopathy. Hypothermia increases the risk of thrombocytopenia as well as coagulopathy [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/4975.html" rel="external">"Perinatal asphyxia in term and late preterm infants", section on 'Therapeutic hypothermia'</a>.)</p><p class="headingAnchor" id="H988221449"><span class="h2">Drug-related thrombocytopenia</span><span class="headingEndMark"> — </span>Neonatal drug-related thrombocytopenia is a result of the following: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet destruction caused by maternal drug-dependent antibodies</strong> – Neonatal thrombocytopenia is mediated by maternal IgG antibodies, which cross the placenta and affect fetal platelets. Drugs associated with maternal immune-mediated platelet destruction include <a class="drug drug_pediatric" data-topicid="12755" href="/d/drug information/12755.html" rel="external">quinidine</a> and antiepileptic agents (eg, <a class="drug drug_pediatric" data-topicid="13113" href="/d/drug information/13113.html" rel="external">carbamazepine</a>, <a class="drug drug_pediatric" data-topicid="12702" href="/d/drug information/12702.html" rel="external">phenytoin</a> and <a class="drug drug_pediatric" data-topicid="12873" href="/d/drug information/12873.html" rel="external">valproic acid</a>) [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal autoimmune thrombocytopenia'</a> and  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'Other causes of thrombocytopenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet destruction caused by neonatal drug-dependent antibodies</strong> – For example, thrombocytopenia due to heparin-associated antiplatelet antibodies is a rare side effect of heparin therapy in newborns. (See  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow suppression</strong> ‒ Bone marrow suppression results in decreased platelet production. This may occur following administration of chemotherapeutic agents to the mother or newborn infant for a malignancy. (See  <a class="medical medical_review" href="/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p>If drug-associated thrombocytopenia is suspected, the offending agent should be withdrawn. Transfusions should be given for low platelet counts (&lt;20,000/microL) or for bleeding. If an immune-mediated condition is suspected, intravenous <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">immune globulin</a> (IVIG) can be used while awaiting confirmation.</p><p class="headingAnchor" id="H40"><span class="h2">Dilution</span><span class="headingEndMark"> — </span>Thrombocytopenia can occur after an exchange transfusion because the relatively large volume of platelet-poor transfused blood can dilute the concentration of circulating platelets. However, the condition for which the exchange transfusion was performed (eg, erythroblastosis fetalis) also can result in thrombocytopenia.</p><p class="headingAnchor" id="H25396378"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>‒ Although neonatal thrombocytopenia is defined as a platelet count &lt;150,000/microL, healthy preterm and term newborns frequently have platelet counts below this defined normal value. (See <a class="local">'Definitions'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> ‒ Predisposing risk factors for neonatal thrombocytopenia include preterm birth, sepsis, asphyxia, intrauterine growth restriction (birth weight [BW] &lt;10<sup>th</sup> percentile for gestational age [GA]), and necrotizing enterocolitis. Both the risk and severity of thrombocytopenia increases with decreasing GA and for infants admitted to the neonatal intensive care unit (NICU). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe thrombocytopenia</strong> ‒ Severe neonatal thrombocytopenia (defined as a platelet count &lt;50,000/microL) is uncommon in the general healthy newborn population. However, the risk increases for infants admitted to the NICU especially for the most preterm infants (BW &lt;1000 g). (See <a class="local">'Definitions'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology classification</strong> ‒ Causes of thrombocytopenia can be classified according to mechanism of thrombocytopenia (due to increased destruction [including sequestration and pooling of platelets] or due to decreased production)  (<a class="graphic graphic_table graphicRef52668" href="/d/graphic/52668.html" rel="external">table 1</a>). Other classification schema use platelet size (large, normal, and small), mode of acquisition (congenital or acquired), timing with early (&lt;72 hours of age) or late (≥72 hours of age) onset, and GA (preterm versus term). (See <a class="local">'Classification of etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Causes of increased platelet destruction in neonates include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neonatal alloimmune thrombocytopenia (see  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal alloimmune thrombocytopenia'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neonatal autoimmune thrombocytopenia (see <a class="local">'Neonatal autoimmune thrombocytopenia'</a> above and  <a class="medical medical_review" href="/d/html/120653.html" rel="external">"Neonatal immune-mediated thrombocytopenia", section on 'Neonatal autoimmune thrombocytopenia'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Sequestration and trapping – Hypersplenism and Kasabach-Merritt phenomenon (see <a class="local">'Sequestration and trapping'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Platelet activation and consumption – Disseminated intravascular coagulation and thrombosis (see <a class="local">'Platelet activation and consumption'</a> above and  <a class="medical medical_review" href="/d/html/5915.html" rel="external">"Disseminated intravascular coagulation in infants and children", section on 'Other etiologies in neonates'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Causes of decreased platelet production in neonates include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Preeclampsia (see <a class="local">'Preeclampsia'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Genetic disorders with defects in megakaryocyte development and differentiation  (<a class="graphic graphic_table graphicRef89962" href="/d/graphic/89962.html" rel="external">table 2</a>) (see <a class="local">'Genetic disorders'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Bone marrow infiltrative diseases – Neonatal leukemia or neuroblastoma (see <a class="local">'Infiltrative disorders'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other causes that include both mechanisms (increased destruction and decreased production) or cannot be classified based on these two mechanisms include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serious bacterial, viral, or fungal infection (see <a class="local">'Infection'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Perinatal asphyxia (see <a class="local">'Asphyxia'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Drug-related thrombocytopenia (see <a class="local">'Drug-related thrombocytopenia'</a> above)</p><p class="bulletIndent3"><span class="glyph">-</span>Dilution (see <a class="local">'Dilution'</a> above)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev 2008; 22:173.</a></li><li><a class="nounderline abstract_t">Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463.</a></li><li><a class="nounderline abstract_t">Sola MC, Del Vecchio A, Rimsza LM. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000; 27:655.</a></li><li><a class="nounderline abstract_t">Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol 2009; 29:130.</a></li><li><a class="nounderline abstract_t">Donato H. Neonatal thrombocytopenia: A review. I. Definitions, differential diagnosis, causes, immune thrombocytopenia. Arch Argent Pediatr 2021; 119:e202.</a></li><li><a class="nounderline abstract_t">Andrew M, Kelton J. Neonatal thrombocytopenia. Clin Perinatol 1984; 11:359.</a></li><li><a class="nounderline abstract_t">Christensen RD, Henry E, Wiedmeier SE, et al. Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 2006; 26:348.</a></li><li><a class="nounderline abstract_t">Castle V, Andrew M, Kelton J, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986; 108:749.</a></li><li><a class="nounderline abstract_t">Sainio S, Järvenpää AL, Renlund M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000; 95:441.</a></li><li><a class="nounderline abstract_t">Stanworth SJ, Clarke P, Watts T, et al. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 2009; 124:e826.</a></li><li><a class="nounderline abstract_t">Baer VL, Lambert DK, Henry E, Christensen RD. Severe Thrombocytopenia in the NICU. Pediatrics 2009; 124:e1095.</a></li><li><a class="nounderline abstract_t">Carr R, Kelly AM, Williamson LM. Neonatal thrombocytopenia and platelet transfusion - a UK perspective. Neonatology 2015; 107:1.</a></li><li><a class="nounderline abstract_t">Resch E, Hinkas O, Urlesberger B, Resch B. Neonatal thrombocytopenia-causes and outcomes following platelet transfusions. Eur J Pediatr 2018; 177:1045.</a></li><li><a class="nounderline abstract_t">Christensen RD, Baer VL, Henry E, et al. Thrombocytopenia in Small-for-Gestational-Age Infants. Pediatrics 2015; 136:e361.</a></li><li><a class="nounderline abstract_t">Sola-Visner M, Sallmon H, Brown R. New insights into the mechanisms of nonimmune thrombocytopenia in neonates. Semin Perinatol 2009; 33:43.</a></li><li><a class="nounderline abstract_t">Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997; 89:4402.</a></li><li><a class="nounderline abstract_t">Tchernia G, Morel-Kopp MC, Yvart J, Kaplan C. Neonatal thrombocytopenia and hidden maternal autoimmunity. Br J Haematol 1993; 84:457.</a></li><li><a class="nounderline abstract_t">Anteby E, Shalev O. Clinical relevance of gestational thrombocytopenia of &lt; 100,000/microliters. Am J Hematol 1994; 47:118.</a></li><li><a class="nounderline abstract_t">George D, Bussel JB. Neonatal thrombocytopenia. Semin Thromb Hemost 1995; 21:276.</a></li><li><a class="nounderline abstract_t">Ververidis M, Kiely EM, Spitz L, et al. The clinical significance of thrombocytopenia in neonates with necrotizing enterocolitis. J Pediatr Surg 2001; 36:799.</a></li><li><a class="nounderline abstract_t">Grainick HR, Williams SB, McKeown LP, et al. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76:1522.</a></li><li><a class="nounderline abstract_t">Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047.</a></li><li><a class="nounderline abstract_t">Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol 2002; 75:9.</a></li><li><a class="nounderline abstract_t">Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996; 40:112.</a></li><li><a class="nounderline abstract_t">Sola MC, Calhoun DA, Hutson AD, Christensen RD. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999; 104:90.</a></li><li><a class="nounderline abstract_t">Delaney J, Nunes GC, Simoneau J, et al. Thrombocytopenia and neonatal outcomes among extremely premature infants exposed to maternal hypertension. Pediatr Blood Cancer 2023; 70:e30131.</a></li><li><a class="nounderline abstract_t">Koenig JM, Christensen RD. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 1989; 321:557.</a></li><li><a class="nounderline abstract_t">Koenig JM, Christensen RD. The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension. Am J Obstet Gynecol 1991; 165:467.</a></li><li><a class="nounderline abstract_t">Henry E, Walker D, Wiedmeier SE, Christensen RD. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A 2007; 143A:42.</a></li><li><a class="nounderline abstract_t">Hohlfeld P, Forestier F, Kaplan C, et al. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994; 84:1851.</a></li><li><a class="nounderline abstract_t">Eissa DS, El-Farrash RA. New insights into thrombopoiesis in neonatal sepsis. Platelets 2013; 24:122.</a></li><li><a class="nounderline abstract_t">Cooper LZ, Green RH, Krugman S, et al. Neonatal thrombocytopenic purpura and other manifestations of rubella contracted in utero. Am J Dis Child 1965; 110:416.</a></li><li><a class="nounderline abstract_t">Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175:1080.</a></li><li><a class="nounderline abstract_t">Christensen RD, Baer VL, Yaish HM. Thrombocytopenia in late preterm and term neonates after perinatal asphyxia. Transfusion 2015; 55:187.</a></li><li><a class="nounderline abstract_t">Ropert JC, Dreyfus M, Dehan M, Tchernia G. [Severe neonatal thrombopenia. Analysis of the etiologic data on 64 cases]. Arch Fr Pediatr 1984; 41:85.</a></li><li><a class="nounderline abstract_t">Oren H, Irken G, Oren B, et al. Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 1994; 61:551.</a></li><li><a class="nounderline abstract_t">Boutaybi N, Steggerda SJ, Smits-Wintjens VE, et al. Early-onset thrombocytopenia in near-term and term infants with perinatal asphyxia. Vox Sang 2014; 106:361.</a></li><li><a class="nounderline abstract_t">Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013; :CD003311.</a></li></ol></div><div id="topicVersionRevision">Topic 4979 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433954" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thrombocytopenia in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413457" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fetal thrombocytopenia and its relation to maternal thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986634" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818663" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34033425" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neonatal thrombocytopenia: A review. I. Definitions, differential diagnosis, causes, immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6378484" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neonatal thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16642027" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3701523" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Frequency and mechanism of neonatal thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711560" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thrombocytopenia in term infants: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841111" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prospective, observational study of outcomes in neonates with severe thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917581" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Severe Thrombocytopenia in the NICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301082" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neonatal thrombocytopenia and platelet transfusion - a UK perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705932" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neonatal thrombocytopenia-causes and outcomes following platelet transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26216323" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thrombocytopenia in Small-for-Gestational-Age Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19167581" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New insights into the mechanisms of nonimmune thrombocytopenia in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192764" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8217797" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Neonatal thrombocytopenia and hidden maternal autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092126" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical relevance of gestational thrombocytopenia of&lt;100,000/microliters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8588155" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Neonatal thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11329593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The clinical significance of thrombocytopenia in neonates with necrotizing enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2932469" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6767976" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843298" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Molecular genetics of type 2 von Willebrand disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8798256" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027717" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36478101" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Thrombocytopenia and neonatal outcomes among extremely premature infants exposed to maternal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2761599" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1714678" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17163522" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080991" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22746320" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : New insights into thrombopoiesis in neonatal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5890932" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Neonatal thrombocytopenic purpura and other manifestations of rubella contracted in utero.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129069" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25082082" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Thrombocytopenia in late preterm and term neonates after perinatal asphyxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6721666" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Severe neonatal thrombopenia. Analysis of the etiologic data on 64 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7744455" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24877222" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Early-onset thrombocytopenia in near-term and term infants with perinatal asphyxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440789" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cooling for newborns with hypoxic ischaemic encephalopathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
